Diligence memo · auto-generated · as of July 2, 2026
Compass Therapeutics, Inc.
Compass Therapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Compass Therapeutics, Inc. operates in Pharma, based in CAMBRIDGE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Compass Therapeutics, Inc. has raised $256M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $195M on 2020-06-17.
Most recent recorded round closed around 2020-06-19.
Valuation (modeled)modeled
Provath models Compass Therapeutics, Inc. at approximately $2.1B (range $288M–$4.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.50× the median modeled value of Series D+ Pharma companies in 2019–2021 (9 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 0 months.
Last raise 6.0 yr ago; this sector typically re-raises about every 16 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 99% of Pharma peers (310 compared).
Modeled value ranks above 95% of those peers.
Closest niche peers: Pyxis Oncology, Inc., Century Therapeutics, Inc., iTeos Therapeutics, Inc., SpringWorks Therapeutics, Inc., Nurix Therapeutics, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.